Children and adults with refractory acute Graft-versus-Host disease respond to treatment with the mesenchymal stromal cell preparation “MSC-FFM”: outcome report of 92 patients
(1) Background: Refractory acute graft-versus-host disease (R-aGvHD) remains a leading cause of death after allogeneic stem cell transplantation. Survival rates of 15% after four years are currently achieved; deaths are only in part due to aGvHD itself, but mostly due to adverse effects of R-aGvHD t...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
5 December 2019
|
| In: |
Cells
Year: 2019, Jahrgang: 8, Heft: 12 |
| ISSN: | 2073-4409 |
| DOI: | 10.3390/cells8121577 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.3390/cells8121577 Verlag: https://www.mdpi.com/2073-4409/8/12/1577 
|
| Verfasserangaben: | Halvard Bonig, Zyrafete Kuçi, Selim Kuçi, Shahrzad Bakhtiar, Oliver Basu, Gesine Bug, Mike Dennis, Johann Greil, Aniko Barta, Krisztián M. Kállay, Peter Lang, Giovanna Lucchini, Raj Pol, Ansgar Schulz, Karl-Walter Sykora, Irene Teichert von Luettichau, Grit Herter-Sprie, Mohammad Ashab Uddin, Phil Jenkin, Abdulrahman Alsultan, Jochen Buechner, Jerry Stein, Agnes Kelemen, Andrea Jarisch, Jan Soerensen, Emilia Salzmann-Manrique, Martin Hutter, Richard Schäfer, Erhard Seifried, Shankara Paneesha, Igor Novitzky-Basso, Aharon Gefen, Neta Nevo, Gernot Beutel, Paul-Gerhardt Schlegel, Thomas Klingebiel and Peter Bader |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1690628251 | ||
| 003 | DE-627 | ||
| 005 | 20230428090202.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200221s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cells8121577 |2 doi | |
| 035 | |a (DE-627)1690628251 | ||
| 035 | |a (DE-599)KXP1690628251 | ||
| 035 | |a (OCoLC)1341307620 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Bönig, Halvard |d 1967- |e VerfasserIn |0 (DE-588)120496100 |0 (DE-627)696726009 |0 (DE-576)29224973X |4 aut | |
| 245 | 1 | 0 | |a Children and adults with refractory acute Graft-versus-Host disease respond to treatment with the mesenchymal stromal cell preparation “MSC-FFM” |b outcome report of 92 patients |c Halvard Bonig, Zyrafete Kuçi, Selim Kuçi, Shahrzad Bakhtiar, Oliver Basu, Gesine Bug, Mike Dennis, Johann Greil, Aniko Barta, Krisztián M. Kállay, Peter Lang, Giovanna Lucchini, Raj Pol, Ansgar Schulz, Karl-Walter Sykora, Irene Teichert von Luettichau, Grit Herter-Sprie, Mohammad Ashab Uddin, Phil Jenkin, Abdulrahman Alsultan, Jochen Buechner, Jerry Stein, Agnes Kelemen, Andrea Jarisch, Jan Soerensen, Emilia Salzmann-Manrique, Martin Hutter, Richard Schäfer, Erhard Seifried, Shankara Paneesha, Igor Novitzky-Basso, Aharon Gefen, Neta Nevo, Gernot Beutel, Paul-Gerhardt Schlegel, Thomas Klingebiel and Peter Bader |
| 264 | 1 | |c 5 December 2019 | |
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 21.02.2020 | ||
| 520 | |a (1) Background: Refractory acute graft-versus-host disease (R-aGvHD) remains a leading cause of death after allogeneic stem cell transplantation. Survival rates of 15% after four years are currently achieved; deaths are only in part due to aGvHD itself, but mostly due to adverse effects of R-aGvHD treatment with immunosuppressive agents as these predispose patients to opportunistic infections and loss of graft-versus-leukemia surveillance resulting in relapse. Mesenchymal stromal cells (MSC) from different tissues and those generated by various protocols have been proposed as a remedy for R-aGvHD but the enthusiasm raised by initial reports has not been ubiquitously reproduced. (2) Methods: We previously reported on a unique MSC product, which was generated from pooled bone marrow mononuclear cells of multiple third-party donors. The products showed dose-to-dose equipotency and greater immunosuppressive capacity than individually expanded MSCs from the same donors. This product, MSC-FFM, has entered clinical routine in Germany where it is licensed with a national hospital exemption authorization. We previously reported satisfying initial clinical outcomes, which we are now updating. The data were collected in our post-approval pharmacovigilance program, i.e., this is not a clinical study and the data is high-level and non-monitored. (3) Results: Follow-up for 92 recipients of MSC-FFM was reported, 88 with GvHD ≥°III, one-third only steroid-refractory and two-thirds therapy resistant (refractory to steroids plus ≥2 additional lines of treatment). A median of three doses of MSC-FFM was administered without apparent toxicity. Overall response rates were 82% and 81% at the first and last evaluation, respectively. At six months, the estimated overall survival was 64%, while the cumulative incidence of death from underlying disease was 3%. (4) Conclusions: MSC-FFM promises to be a safe and efficient treatment for severe R-aGvHD. | ||
| 650 | 4 | |a cell therapy | |
| 650 | 4 | |a graft-versus host | |
| 650 | 4 | |a hospital exemption | |
| 650 | 4 | |a mesenchymal stromal cell | |
| 650 | 4 | |a refractory aGvHD | |
| 650 | 4 | |a steroid-resistant aGvHD | |
| 650 | 4 | |a transplantation | |
| 700 | 1 | |a Greil, Johann |e VerfasserIn |0 (DE-588)1078331979 |0 (DE-627)838332455 |0 (DE-576)450711498 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cells |d Basel : MDPI, 2012 |g 8(2019,12) Artikel-Nummer 1577, 13 Seiten |h Online-Ressource |w (DE-627)718622081 |w (DE-600)2661518-6 |w (DE-576)365412112 |x 2073-4409 |7 nnas |a Children and adults with refractory acute Graft-versus-Host disease respond to treatment with the mesenchymal stromal cell preparation “MSC-FFM” outcome report of 92 patients |
| 773 | 1 | 8 | |g volume:8 |g year:2019 |g number:12 |g extent:13 |a Children and adults with refractory acute Graft-versus-Host disease respond to treatment with the mesenchymal stromal cell preparation “MSC-FFM” outcome report of 92 patients |
| 856 | 4 | 0 | |u https://doi.org/10.3390/cells8121577 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://www.mdpi.com/2073-4409/8/12/1577 |x Verlag |
| 951 | |a AR | ||
| 992 | |a 20200221 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 1078331979 |a Greil, Johann |m 1078331979:Greil, Johann |d 910000 |d 910500 |e 910000PG1078331979 |e 910500PG1078331979 |k 0/910000/ |k 1/910000/910500/ |p 8 | ||
| 999 | |a KXP-PPN1690628251 |e 3597327524 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"eki":["1690628251"],"doi":["10.3390/cells8121577"]},"origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"5 December 2019"}],"name":{"displayForm":["Halvard Bonig, Zyrafete Kuçi, Selim Kuçi, Shahrzad Bakhtiar, Oliver Basu, Gesine Bug, Mike Dennis, Johann Greil, Aniko Barta, Krisztián M. Kállay, Peter Lang, Giovanna Lucchini, Raj Pol, Ansgar Schulz, Karl-Walter Sykora, Irene Teichert von Luettichau, Grit Herter-Sprie, Mohammad Ashab Uddin, Phil Jenkin, Abdulrahman Alsultan, Jochen Buechner, Jerry Stein, Agnes Kelemen, Andrea Jarisch, Jan Soerensen, Emilia Salzmann-Manrique, Martin Hutter, Richard Schäfer, Erhard Seifried, Shankara Paneesha, Igor Novitzky-Basso, Aharon Gefen, Neta Nevo, Gernot Beutel, Paul-Gerhardt Schlegel, Thomas Klingebiel and Peter Bader"]},"relHost":[{"pubHistory":["1.2012 -"],"part":{"volume":"8","text":"8(2019,12) Artikel-Nummer 1577, 13 Seiten","extent":"13","year":"2019","issue":"12"},"note":["Gesehen am 09.05.12"],"disp":"Children and adults with refractory acute Graft-versus-Host disease respond to treatment with the mesenchymal stromal cell preparation “MSC-FFM” outcome report of 92 patientsCells","type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"recId":"718622081","title":[{"title_sort":"Cells","subtitle":"open access journal","title":"Cells"}],"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedDisp":"2012-","dateIssuedKey":"2012","publisher":"MDPI","publisherPlace":"Basel"}],"id":{"issn":["2073-4409"],"zdb":["2661518-6"],"eki":["718622081"]}}],"physDesc":[{"extent":"13 S."}],"title":[{"title":"Children and adults with refractory acute Graft-versus-Host disease respond to treatment with the mesenchymal stromal cell preparation “MSC-FFM”","subtitle":"outcome report of 92 patients","title_sort":"Children and adults with refractory acute Graft-versus-Host disease respond to treatment with the mesenchymal stromal cell preparation “MSC-FFM”"}],"person":[{"given":"Halvard","family":"Bönig","role":"aut","roleDisplay":"VerfasserIn","display":"Bönig, Halvard"},{"given":"Johann","family":"Greil","role":"aut","roleDisplay":"VerfasserIn","display":"Greil, Johann"}],"recId":"1690628251","language":["eng"],"note":["Gesehen am 21.02.2020"],"type":{"media":"Online-Ressource","bibl":"article-journal"}} | ||
| SRT | |a BOENIGHALVCHILDRENAN5201 | ||